Heron Therap (HRTX)
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The compan...
- Open
- 0.3334
- High
- 0.3350
- Low
- 0.3030
- Prev. Close
- 0.3350
- Volume
- 9.77M
- Turnover
- 3.10M
- Avg Price
- 0.3169
- Bid/Ask Ratio
- --
- Amplitude
- 9.55%
- 52wk High
- 1.5750
- Volume Ratio
- 6.34
- Turnover Ratio
- 7.28%
Heron Therap Analyst Rating
View moreForecast & Rating
Aug 10, 2026Price forecast
$2.00517.67%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 18 hours ago
Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold
- Quartr · 1 day ago, 07:11 AM
HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty
- PUBT · 1 day ago, 07:09 AM
Heron Q2 FY26 net loss widens to $5.49 million; net sales rise 1.3% to $37.67 million
- PUBT · 1 day ago, 07:03 AM
Heron Therapeutics amends Hercules Capital credit facility, cuts principal by $13.5 million
- Earnings Watch · 1 day ago, 07:02 AM
Heron Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 37.67 M
- Market Beat · Aug 3 at 09:56 AM
Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday
